LGM
IOBT

Logos Global Management’s IO Biotech IOBT Stock Holding History

Logos Global Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-493,827
Closed -$519K – 60
2024
Q3 		$519K Hold
493,827
– – 0.06% 53
2024
Q2 		$578K Hold
493,827
– – 0.05% 55
2024
Q1 		$854K Hold
493,827
– – 0.07% 54
2023
Q4 		$928K Hold
493,827
– – 0.09% 51
2023
Q3 		$696K Buy
+493,827
New +$868K 0.09% 51

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Logos Global Management's IOBT Position: Q4 2024 in Review

Logos Global Management sold out of IO Biotech (IOBT) in Q4 2024, closing a stake of 493,827 shares — an estimated $519K sold.

Logos Global Management first reported a position in IOBT in Q3 2023 and held it in 5 quarters. The position peaked at $928K in Q4 2023. 27 funds tracked by Wall St. Rank hold IOBT as of Q4 2024.

  • Logos Global Management reported no remaining IO Biotech position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 493,827 IO Biotech shares in Q4 2024, an estimated $519K.
  • Logos Global Management first reported a position in IO Biotech in Q3 2023 and held it in 5 quarters.
  • Logos Global Management's IO Biotech position peaked at $928K in Q4 2023.
  • 27 funds tracked by Wall St. Rank held IO Biotech as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.